![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1733219
¼¼°èÀÇ Ä¸½¶ ³»½Ã°æ ½ÃÀå : ¾×¼¼¼¸®º°, Á¦Ç°º°, ¿ëµµº°, Áö¿ªº°(2026-2032³â)Capsule Endoscopy Market By Accessories (Wireless Capsule, Workstation and Receiver), By Product (Small Bowel, Esophageal), Application (Crohn¢¥s Disease, OGIB (Obscure Gastrointestinal Bleeding)), & Region for 2026-2032 |
Å©·Ðº´ ¹× ¼ÒȰü ÃâÇ÷°ú °°Àº Áúº´ Áõ°¡´Â ĸ½¶ ³»½Ã°æÀÇ Ã¤ÅÃÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ĸ½¶ ¼³°è ¹× À̹Ì¡ ±â¼úÀÇ Çõ½ÅÀº Áø´Ü Á¤È®µµ¿Í ȯÀÚ °æÇèÀ» Çâ»ó½ÃÄÑ ½ÃÀå ±Ô¸ð°¡ 2024³â 2¾ï 9,230¸¸ ´Þ·¯¸¦ µ¹ÆÄÇϰí 2032³â±îÁö ¾à 9¾ï 7,156¸¸ ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
ÀÌ¿Í ´õºÒ¾î, ¼ÒȰü °Ç° ¹× »ç¿ë °¡´ÉÇÑ Áø´Ü ¿É¼Ç¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼ ĸ½¶ ³»½Ã°æÀÇ Ã¤ÅÃÀÌ °¡¼Óȵǰí ÀÖ½À´Ï´Ù. ºñħ½ÀÀû Áø´Ü ¹æ¹ý¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁü¿¡ µû¶ó ĸ½¶ ³»½Ã°æÀÇ È¯ÀÚ ¼ö¿ë°ú »ç¿ëÀÌ Áõ°¡ÇÏ¿© 2026³âºÎÅÍ 2032³â±îÁö 16.20%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ½ÃÀåÀÌ ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
ĸ½¶ ³»½Ã°æ ½ÃÀå Á¤ÀÇ/°³¿ä
ĸ½¶ ³»½Ã°æ °Ë»ç´Â À§Àå°üÀÇ ÁÖÇà ¿µ»óÀ» ÃÔ¿µÇÏ´Â ¼ÒÇü Á¤Á¦ Å©±âÀÇ Ä«¸Þ¶ó¸¦ »ïŰ´Â ÃÖ¼Ò Ä§½ÀÀû Áø´Ü ÀýÂ÷ÀÔ´Ï´Ù. ÀϹÝÀûÀ¸·Î ±¤¿ø°ú Ä«¸Þ¶ó°¡ ÀåÂøµÈ ÀÌ ÀåÄ¡´Â À̹ÌÁö¸¦ ¹«¼±À¸·Î ¿ÜºÎ ±â·Ï ÀåÄ¡·Î Àü¼ÛÇÕ´Ï´Ù. ÀÌ ±â¼úÀº ¼ÒÀå°ú °°ÀÌ ±âÁ¸ÀÇ ³»½Ã°æÀ¸·Î´Â µµ´ÞÇϱ⠾î·Á¿î ¼ÒȰü ºÎÀ§¸¦ »ó¼¼ÇÏ°Ô ½Ã°¢ÈÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù.
ĸ½¶ ³»½Ã°æ °Ë»ç´Â ÁÖ·Î ¼ÒȰü ÃâÇ÷, Å©·Ðº´, ¼ÒÀå Á¾¾ç µîÀÇ Áø´Ü¿¡ »ç¿ëµË´Ï´Ù. ¿øÀÎÀ» ¾Ë ¼ö ¾ø´Â ¼Òȱâ Áõ»óÀ» °æÇèÇϴ ȯÀÚ¿¡°Ô ƯÈ÷ À¯¿ëÇϸç, ¸¹Àº º´º¯ÀÌ ¹ß°ßµÇÁö ¾ÊÀ» ¼ö ÀÖ´Â ¼ÒÀåÀ» Á¾ÇÕÀûÀ¸·Î º¼ ¼ö Àֱ⠶§¹®¿¡ ƯÈ÷ À¯¿ëÇÕ´Ï´Ù. ÀÌ °Ë»ç´Â ÀϹÝÀûÀ¸·Î ¾ÈÀüÇÏ°í ºñħ½ÀÀûÀ̸ç ÁøÁ¤Á¦°¡ ÇÊ¿äÇÏÁö ¾Ê±â ¶§¹®¿¡ ¸¹Àº ȯÀڵ鿡°Ô ¸Å·ÂÀûÀÎ ¼±ÅÃÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.
¼Òȱâ ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ĸ½¶ ³»½Ã°æ ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀÔ´Ï´Ù. ¹Ì±¹ ±¹¸³´ç´¢º´-¼Òȱâ-½ÅÀ庴 ¿¬±¸¼Ò¿¡ µû¸£¸é, ¹Ì±¹¿¡¼´Â ¾à 6,000¸¸-7,000¸¸ ¸íÀÌ ¼Òȱâ ÁúȯÀ» ¾Î°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ È¯ÀÚ ¼ö Áõ°¡·Î ÀÎÇØ Àúħ½ÀÀû Áø´Ü µµ±¸¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. 2024³â 3¿ù, ¸ÞµåÆ®·Î´ÐÀº Çâ»óµÈ ¿µ»ó ó¸® ±â´É°ú Çâ»óµÈ ¹èÅ͸® ¼ö¸íÀ» Ư¡À¸·Î ÇÏ´Â »õ·Î¿î PillCam(TM) SB4 ½Ã½ºÅÛÀ» Ãâ½ÃÇÑ´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. ¹ßÇ¥Çß½À´Ï´Ù.
ĸ½¶ ³»½Ã°æ ½Ã½ºÅÛÀÇ ±â¼úÀû Áøº¸°¡ ½ÃÀå ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. °íÇØ»óµµ Ä«¸Þ¶ó, ´õ ±ä ¹èÅ͸® ¼ö¸í, ÀΰøÁö´É Áö¿ø À̹ÌÁö ºÐ¼®°ú °°Àº ±â¼ú Çõ½ÅÀº Áø´Ü Á¤È®µµ¸¦ Çâ»ó½Ã۰í ĸ½¶ ³»½Ã°æÀÇ ¿ëµµ¸¦ È®ÀåÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °³¹ßÀº ƯÈ÷ ¼ÒÀå Á¾¾ç°ú ºÒ¸íÈ®ÇÑ ¼ÒȰü ÃâÇ÷À» °¨ÁöÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)´Â 2020³â¿¡´Â ´ëÀå¾ÏÀÌ ¼¼°è¿¡¼ ¼¼ ¹øÂ°·Î ¸¹Àº ¾ÏÀÌ µÉ °ÍÀ̸ç, 193¸¸ ¸íÀÌ »õ·Î ¹ßº´ÇÒ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖ½À´Ï´Ù. ¿Ã¸²Çª½ºÇѱ¹Àº 2024³â 2¿ù, AI¸¦ Ȱ¿ëÇÑ º´º¯ °ËÃâ ¾Ë°í¸®ÁòÀ» žÀçÇÑ Â÷¼¼´ë ĸ½¶ ³»½Ã°æ Ç÷§ÆûÀ» ¹ßÇ¥Çß½À´Ï´Ù.
°¡Ä¡ ±â¹Ý ÀÇ·á·ÎÀÇ Àüȯ°ú ¿ø°Ý ÀÇ·áÀÇ µµÀÔ È®´ë´Â ĸ½¶ ³»½Ã°æ ½ÃÀåÀ» ¹ßÀü½Ã۰í ÀÖ½À´Ï´Ù. ĸ½¶ ³»½Ã°æ °Ë»ç´Â ±âÁ¸ÀÇ ³»½Ã°æ ½Ã¼ú¿¡ ´ëÇÑ ºñ¿ë È¿À²ÀûÀÎ ´ë¾ÈÀ» Á¦°øÇÏ¿© ÀÔ¿ø ¹× ¸¶ÃëÀÇ Çʿ伺À» ÁÙ¿©ÁÝ´Ï´Ù. ¸ÞµðÄɾî&¸ÞµðÄÉÀÌµå ¼ºñ½º ¼¾ÅÍ´Â Äڷγª19 ÆÒµ¥¹Í ±â°£ µ¿¾È ¿ø°Ý ÀÇ·á ¹æ¹®ÀÌ 2019³â ¾à 840¸¸ °Ç¿¡¼ 2020³â 5,270¸¸ °ÇÀ¸·Î 63¹è Áõ°¡Çß´Ù°í º¸°íÇß½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â Áö¼ÓµÇ°í ÀÖÀ¸¸ç, ¿ø°Ý ĸ½¶ ³»½Ã°æ ½Ã¼úÀÇ ±âȸ¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù.
ĸ½¶ ³»½Ã°æ ½ÃÀåÀº ÀÌ ±â¼ú°ú °ü·ÃµÈ ³ôÀº ºñ¿ëÀ¸·Î ÀÎÇØ Å« ÇѰ迡 Á÷¸éÇØ ÀÖ½À´Ï´Ù. ÇÊ¿äÇÑ ¿µ»ó ó¸® ¹× ÆÇµ¶ ¼ÒÇÁÆ®¿þ¾î»Ó¸¸ ¾Æ´Ï¶ó Àåºñ ÀÚüµµ °í°¡ÀÏ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °æÁ¦Àû ºÎ´ãÀº ƯÈ÷ ÀÇ·á ¿¹»êÀÌ ºÎÁ·ÇÑ °³¹ßµµ»ó±¹¿¡¼ ȯÀÚ¿Í ÀÇ·á ½Ã¼³ÀÇ Á¢±Ù¼ºÀ» Á¦ÇÑÇÏ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ³ôÀº ºñ¿ëÀº ÀÇ·á ¼ºñ½º Á¦°ø¾÷üµéÀÌ ÀÌ ±â¼úÀ» äÅÃÇÏ´Â °ÍÀ» ÁÖÀúÇÏ°Ô ¸¸µé°í, Àüü ½ÃÀåÀÇ ¼ºÀåÀ» Á¦ÇÑÇÏ´Â ¿äÀÎÀÌ µÇ±âµµ ÇÕ´Ï´Ù.
¶Ç ´Ù¸¥ Àå¾Ö ¿äÀÎÀº ĸ½¶ ³»½Ã°æ °Ë»ç¿¡ ´ëÇÑ »ó´ëÀûÀ¸·Î Á¦ÇÑÀûÀÎ º¸»ó ¿É¼ÇÀÌ ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. ¸¹Àº º¸Çè»ç°¡ ºñ¿ëÀ» ¿ÏÀüÈ÷ º¸ÀåÇÏÁö ¾Ê±â ¶§¹®¿¡ ȯÀÚ¿Í ÀÇ»ç ¸ðµÎ ÀÌ Áø´Ü µµ±¸¸¦ ¼±ÅÃÇÏ·Á´Â ÀÇÁö°¡ ¾àÇØÁú ¼ö ÀÖ½À´Ï´Ù. Ç¥ÁØÈµÈ »óȯ °¡À̵å¶óÀÎÀÇ ºÎÀç´Â »óȲÀ» ´õ¿í º¹ÀâÇÏ°Ô ¸¸µé°í ÀÖÀ¸¸ç, ÀÇ·á ¼ºñ½º Á¦°ø¾÷ü°¡ ĸ½¶ ³»½Ã°æ °Ë»ç ºñ¿ëÀ» ±âÁ¸ ¹æ½Ä°ú ºñ±³ÇÏ¿© Á¤´çÈÇÏ±â ¾î·Æ°Ô ¸¸µì´Ï´Ù.
¶ÇÇÑ, ½ÃÀåÀº µ¥ÀÌÅÍ °ü¸® ¹× ºÐ¼®°ú °ü·ÃµÈ ±â¼úÀû ¹®Á¦·Î ÀÎÇØ ½ÃÀå ¼ºÀåÀ» ÀúÇØÇϰí ÀÖ½À´Ï´Ù. ĸ½¶ ³»½Ã°æ¿¡¼ »ý¼ºµÇ´Â ¹æ´ëÇÑ µ¥ÀÌÅʹ ó¸® ¹× ÇØ¼®À» À§ÇÑ °í±Þ ¼ÒÇÁÆ®¿þ¾î°¡ ÇÊ¿äÇÕ´Ï´Ù. ±×·¯³ª ÇöÀç ¿µ»ó ºÐ¼® ¹× Áø´Ü Á¤È®µµ¸¦ À§ÇÑ ±â´ÉÀº ÀϰüµÇÁö ¾ÊÀ» ¼ö ÀÖÀ¸¸ç, ÀÌ´Â Áø´ÜÀ» ³õÄ¡°Å³ª ÈÄ¼Ó Á¶Ä¡ÀÇ Çʿ伺¿¡ ´ëÇÑ ¿ì·Á·Î À̾îÁú ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÒÈ®½Ç¼ºÀº ÀÇ·á Àü¹®°¡µéÀÌ Ä¸½¶ ³»½Ã°æÀ» ÁÖ¿ä Áø´Ü µµ±¸·Î »ç¿ëÇÏ´Â °ÍÀ» ÁÖÀúÇÏ°Ô ¸¸µé°í ½ÃÀå µµÀÔ¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù.
Rising cases of conditions like Crohn's disease and gastrointestinal bleeding is propelling the adoption of capsule endoscopy. Innovations in capsule design and imaging technology enhance diagnostic accuracy and patient experience is driving the market size surpass USD 292.3 Million valued in 2024 to reach a valuation of around USD 971.56 Million by 2032.
In addition to this, increased awareness about gastrointestinal health and available diagnostic options is spurring up the adoption of capsule endoscopy. The rising preference for non-invasive diagnostic methods drives patient acceptance and usage of capsule endoscopy is enabling the market grow at a CAGR of 16.20% from 2026 to 2032.
Capsule Endoscopy Market: Definition/ Overview
Capsule endoscopy is a minimally invasive diagnostic procedure that involves swallowing a small, pill-sized camera that captures images of the gastrointestinal (GI) tract as it travels through. The device, typically equipped with a light source and camera, transmits images wirelessly to an external recorder. This technique allows for detailed visualization of areas of the GI tract that are difficult to reach with traditional endoscopic methods, such as the small intestine.
Capsule endoscopy is primarily used for diagnosing conditions such as gastrointestinal bleeding, Crohn's disease, and small bowel tumors. It is particularly beneficial for patients who experience unexplained GI symptoms, as it provides a comprehensive view of the small intestine, where many pathologies may go unnoticed. The procedure is generally safe, non-invasive, and does not require sedation, making it an attractive option for many patients.
The rising prevalence of gastrointestinal disorders is a key driver of the capsule endoscopy market. According to the National Institute of Diabetes and Digestive and Kidney Diseases, approximately 60 to 70 million people in the United States are affected by digestive diseases. This increasing patient population has led to a growing demand for minimally invasive diagnostic tools. Capsule endoscopy offers a painless and efficient method for visualizing the entire small intestine, which is challenging to examine using traditional endoscopic techniques. In March 2024, Medtronic announced the launch of their new PillCam(TM) SB4 system, featuring enhanced imaging capabilities and improved battery life.
Technological advancements in capsule endoscopy systems are fueling market growth. Innovations such as higher resolution cameras, longer battery life, and artificial intelligence-assisted image analysis are improving diagnostic accuracy and expanding the applications of capsule endoscopy. These developments are particularly crucial for detecting small bowel tumors and obscure gastrointestinal bleeding. The World Health Organization reported that colorectal cancer was the third most common cancer worldwide in 2020, with 1.93 million new cases. In response to this growing need, Olympus Corporation unveiled its next-generation capsule endoscopy platform in February 2024, incorporating AI-powered lesion detection algorithms.
The shift towards value-based healthcare and the increasing adoption of telemedicine are driving the capsule endoscopy market forward. Capsule endoscopy offers a cost-effective alternative to traditional endoscopic procedures, reducing the need for hospital stays and anesthesia. The Centers for Medicare & Medicaid Services reported that telehealth visits increased by 63-fold during the COVID-19 pandemic, from approximately 840,000 in 2019 to 52.7 million in 2020. This trend has persisted, creating opportunities for remote capsule endoscopy procedures.
The capsule endoscopy market faces significant limitations due to the high costs associated with the technology. The devices themselves, along with the necessary imaging and interpretation software, can be expensive. This financial burden often restricts accessibility for patients and healthcare facilities, particularly in developing regions where healthcare budgets are tighter. The high cost can lead to hesitancy among providers to adopt the technology, limiting its overall market growth.
Another restraint is the relatively limited reimbursement options available for capsule endoscopy procedures. Many insurance providers do not fully cover the costs, which can discourage both patients and physicians from opting for this diagnostic tool. The lack of standardized guidelines for reimbursement further complicates the situation, making it challenging for healthcare providers to justify the expense of capsule endoscopy compared to traditional methods.
Additionally, the market is hindered by technological challenges related to data management and analysis. The vast amount of data generated by capsule endoscopes requires sophisticated software for processing and interpretation. However, the current capabilities for image analysis and diagnostic accuracy can be inconsistent, leading to concerns about missed diagnoses or the need for follow-up procedures. This uncertainty can deter healthcare professionals from relying on capsule endoscopy as a primary diagnostic tool, impacting market adoption.
Wireless capsule endoscopy has emerged as the dominant technology in the capsule endoscopy market, revolutionizing gastrointestinal diagnostics. This non-invasive method allows for comprehensive visualization of the small intestine, which is challenging to examine using traditional endoscopic techniques. The U.S. Food and Drug Administration (FDA) reports that since the approval of the first wireless capsule endoscopy system in 2001, over 2 million procedures have been performed worldwide. The technology's ability to provide high-resolution images while minimizing patient discomfort has led to its widespread adoption.
The wireless capsule's dominance is further reinforced by its expanding applications beyond small bowel examination. Recent advancements have enabled its use in esophageal and colon screenings, broadening its clinical utility. According to the National Institute of Diabetes and Digestive and Kidney Diseases, colorectal cancer is the third most common cancer in both men and women in the United States, with an estimated 151,030 new cases in 2022. This prevalence underscores the importance of effective screening tools like wireless capsule endoscopy.
Obscure Gastrointestinal Bleeding (OGIB) has emerged as the dominant application in the capsule endoscopy market, driving significant growth and innovation. OGIB, defined as persistent or recurrent bleeding from the gastrointestinal tract with no identifiable source through conventional endoscopy, presents a unique diagnostic challenge that capsule endoscopy is uniquely positioned to address. According to the National Institute of Diabetes and Digestive and Kidney Diseases, OGIB accounts for approximately 5% of all gastrointestinal bleeding cases, with the small bowel being the most common source. Capsule endoscopy's ability to visualize the entire small intestine has made it an invaluable tool in diagnosing OGIB.
The prevalence of OGIB and its impact on patient quality of life have spurred technological advancements in capsule endoscopy systems. These improvements include higher resolution cameras, longer operating times, and artificial intelligence-assisted image analysis, all aimed at enhancing the detection of subtle bleeding sources. The American Journal of Gastroenterology reported that capsule endoscopy has a diagnostic yield of up to 67% in patients with OGIB, significantly higher than other diagnostic modalities. This high diagnostic yield has solidified capsule endoscopy's position as the gold standard for OGIB diagnosis.
North America dominates the capsule endoscopy market, driven by a high prevalence of gastrointestinal disorders and advanced healthcare infrastructure. The region's leadership is underpinned by early adoption of innovative medical technologies and a robust reimbursement landscape. According to the Centers for Disease Control and Prevention (CDC), colorectal cancer is the third most common cancer in both men and women in the United States, with 151,030 new cases reported in 2022. This high incidence rate has fueled demand for advanced diagnostic tools like capsule endoscopy. In January 2024, Medtronic, a key player in the North American market, launched its next-generation PillCam(TM) SB4 system, featuring improved image resolution and a longer battery life, further solidifying the region's dominance in capsule endoscopy technology.
The presence of major market players and ongoing research and development activities contribute significantly to North America's leading position. The region boasts a high concentration of key manufacturers, fostering innovation and competitive pricing. The U.S. Food and Drug Administration (FDA) reported that since the first capsule endoscopy system approval in 2001, over 2 million procedures have been performed in the United States alone. This high adoption rate reflects the region's advanced healthcare system and willingness to embrace new technologies. In March 2024, Olympus Corporation announced the opening of a new research and development center in California, focusing on AI-powered image analysis for capsule endoscopy, highlighting the region's continued investment in advancing this technology.
The Asia Pacific region is experiencing rapid growth in the capsule endoscopy market, driven by increasing healthcare expenditure, rising awareness of gastrointestinal diseases, and improving access to advanced medical technologies. Countries like China, Japan, and India are at the forefront of this expansion, with their large populations and growing middle class contributing to increased demand for minimally invasive diagnostic tools. According to the World Health Organization, the incidence of colorectal cancer in Asia is expected to increase by 60% by 2030, reaching 1.5 million new cases annually. This alarming projection has spurred investment in early detection technologies.
Technological advancements and localization efforts by key market players are fueling the rapid growth of capsule endoscopy in Asia Pacific. The region's tech-savvy population and strong manufacturing capabilities have created a fertile ground for innovation in medical devices. The Indian Council of Medical Research reported that in 2023, there was a 15% increase in the adoption of capsule endoscopy procedures across major Indian hospitals compared to the previous year. This trend reflects the growing acceptance of the technology among healthcare providers and patients alike.
The capsule endoscopy market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.
The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the capsule endoscopy market include: